Literature DB >> 3540828

Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity.

R B Fick, R A Robbins, S U Squier, W E Schoderbek, W D Russ.   

Abstract

Experiments performed in vitro have demonstrated that leukocyte neutral proteases produce an important mediator of inflammation, C5a, by proteolysis of the C5 component of the complement system. Cystic fibrosis (CF) lung fluids were characterized by high levels of neutrophils (39% of total cells versus 2% in normals) and contained significantly elevated amounts of elastolytic activity (mean 17.7 ng/micrograms total protein) compared to the lung fluids obtained from normal volunteers (0.2 ng elastolytic activity/micrograms protein, p = 0.001). The objective of these studies was to determine if complement activation and complement-derived chemotactic activity are present in CF lung fluids. C3c peptide representing activation of C3 could not be identified in the bronchial-alveolar lung lavage fluids of normal subjects but was readily identified by means of crossed immunoelectrophoresis in CF lung fluids (n = 9, mean 49% of C3); the mean level of C3 was decreased in CF lung specimens. Chemotactic activity was significantly elevated in lung fluids of the CF patients when compared to normal lung fluids. Using gel-filtration chromatography and a sensitive radioimmunoassay the chemotaxin present in CF specimens was identified as the anaphylatoxin C5a. C5a levels in the bronchial-alveolar lavage fluids of CF patients was inversely related to volume in liters expired in 1 s of a forced expiratory maneuver expressed as a percent of vital capacity determined from a forced expiratory maneuver (r = -0.72). Because there was a direct relationship between the total elastolytic activity present in CF airways and the concentration of C5a (r = 0.97, p = 0.03), it was postulated that airway proteases with elastolytic activity also cleave C5, nonimmunologically producing C5a. Detailed inhibition assays revealed that much of the total elastolytic activity had the inhibition profile of a serine proteinase. The levels of the serine proteinases were closely correlated with the numbers of neutrophilic leukocytes present per ml of lavage fluid (r = 0.7, p = 0.05). However, inhibitors of leukocyte serine proteases did not prevent the generation of additional chemotactic activity and the proteolysis of radiolabeled C5 substrate was not prevented by inhibitors of neutrophil elastase. Although the purified metalloelastase of Pseudomonas aeruginosa was active on cell-bound and free C5 yielding C5a, inhibition of this bacterial protease in CF lung fluids only partially blocked cleavage of the alpha- and beta-chains of C5.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3540828     DOI: 10.1203/00006450-198612000-00014

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  28 in total

Review 1.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

2.  Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis.

Authors:  R H Lawrence; T C Sorrelli
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

3.  Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.

Authors:  C M Costello; C M O'Connor; G A Finlay; P Shiels; M X FitzGerald; J P Hayes
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

4.  Inflammatory bronchopulmonary response of preterm infants with microbial colonisation of the airways at birth.

Authors:  P Groneck; B Goetze-Speer; C P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

Review 5.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 6.  Role of corticosteroids in cystic fibrosis lung disease.

Authors:  I M Balfour-Lynn; R Dinwiddie
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

7.  Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line.

Authors:  S Varsano; M Kaminsky; M Kaiser; L Rashkovsky
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

8.  Corticosteroid treatment in cystic fibrosis.

Authors:  J F Price; P Greally
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

Review 9.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.